Sports
Imran Patel is survived by his wife and three young daughters and his youngest is just four months..
Currently, 12 lakh booster doses of GemCOVAC-OM are accessible at the Central Drugs Laboratory (CDL), Kasauli, which is in charge of national regulations for indigenously produced vaccines for the domestic market.
Digital Desk: The Drugs Controller General of India (DCGI)
granted emergency use authorization to Pune-based Gennova Biopharmaceuticals on
Tuesday for its mRNA COVID-19 booster vaccine, GEMCOVAC-OM, against the Omicron
strain of SARS-CoV2. "In the country, a booster dose against SARS-CoV2 is
still required." Original vaccinations were ineffective against the
Omicron lineage. "An updated vaccine is required, and yes, we anticipate
sufficient market demand for the precautionary dose," Dr Sanjay Singh, CEO
of Pune-based Gennova Biopharmaceuticals Ltd, said today.
The debut is scheduled for two to three weeks in New Delhi,
where pricing and estimated demand will be announced. Currently, 12 lakh
booster doses of GemCOVAC-OM are accessible at the Central Drugs Laboratory
(CDL), Kasauli, which is in charge of national regulations for indigenously
produced vaccines for the domestic market.
Also Read : Ram Lalla idol to be installed in Ayodhya in January next year
More than 220 crore doses of Covid vaccine have been
provided in the country so far, and according to government figures,
approximately 24% of the fully vaccinated population in the country had gotten
booster shots as of April this year. According to the Union Ministry of Health
and Welfare, active Covid cases now account for 0.01 percent of total
infections. Dr Singh is undeterred by the stream of questions presented at a
virtual media conference on the importance of a booster dose in such a setting,
with Covid lying low and a tepid adoption of boosters across the country.
"In phase 3 clinical trials conducted at 20 centres across 13 cities in
India, GEMCOVAC-OM demonstrated robust immune responses." GEMCOVAC-OM was
administered to roughly 3,000 people in Phase II/III trials, and the vaccine
was shown to be safe and well tolerated. The current vaccinations approved for
use as precautionary/booster doses are meant to protect against the ancestral
strain of SARS-CoV-2. Although they will raise antibody titers, their potential
to neutralise the circulating SARS-CoV-2 Omicron form is limited. Developing
antibodies and memory immune responses unique to the Omicron variety might
minimise the likelihood of infection and hospitalisation, as well as avoid
subsequent pandemic waves. "The Made-in-India GEMCOVAC-OM addresses this
gap specifically," he stated.
"We are the third company, after top US biotech firms
Moderna and Pfizer, to develop an mRNA COVID-19 booster vaccine - the first in
India - against the highly transmissible Omicron variant," Dr Singh added.
Those above the age of 18 can receive the vaccine as a
booster dose. Individuals who have gotten two doses of either Covaxin or
Covishield can receive this safely. The vaccine is lyophilized (freeze-dried)
and stable at 2-8 °C.
"There is an acceptance that COVID-19 will persist and
mutate, and that we must be prepared with vaccines to deal with emerging
variants." "The mRNA platform, which was developed in collaboration
with the Department of Biotechnology, Government of India, allows for a quick
turnaround for vaccine development for any future variants of concern, if
any," he added. "Gennova has successfully developed India's first
Omicron-variant vaccine within a few months," stated Samit Mehta, COO of
Gennova Biopharmaceuticals Limited. Given the global accessibility issues for
the COVID-19 vaccines, we are pleased to provide a vaccination based on
cutting-edge technology, the mRNA."
Leave A Comment